Drug Profile
Guretolimod - Sumitomo Pharma America
Alternative Names: DSP-0509Latest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator Boston Biomedical
- Developer Sumitomo Pharma America
- Class Acetic acids; Amines; Antineoplastics; Fluorinated hydrocarbons; Phenyl ethers; Pyrimidines; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 16 Feb 2023 Sumitomo Pharma terminates a phase I/II trial in Solid tumours in Japan (IV) prior to January 2023
- 31 Jan 2023 Sumitomo Pharma terminates a phase I/II trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in US (IV) prior to January 2023
- 31 Jan 2023 Sumitomo Pharma terminates a phase I/II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) prior to January 2023